Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1

Background: Survivin, a novel inhibitor of apoptosis, is one of the most cancer-specific proteins identified to date. In this study we (a) evaluated the association between survivin and HER2, vascular endothelial growth factor (VEGF) and uPA/PAI-1 expression and (b) defined its effect on clinical ou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2006-04, Vol.17 (4), p.597-604
Hauptverfasser:	Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.-J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J., Duffy, M.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences breast cancer Breast Neoplasms - metabolism Clinical outcomes Cohort Studies Female Gynecology. Andrology. Obstetrics HER2 Humans Inhibitor of Apoptosis Proteins Mammary gland diseases Medical sciences Microtubule-Associated Proteins - metabolism Neoplasm Proteins - metabolism Pharmacology. Drug treatments Plasminogen Activator Inhibitor 1 - metabolism prognosis Receptor, ErbB-2 - metabolism Survivin Treatment Outcome Tumors uPA/PAI-1 Urokinase-Type Plasminogen Activator - metabolism Vascular Endothelial Growth Factor A - metabolism VEGF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!